Cell Line Glycoengineering

Cell Line Glycoengineering

CD BioGlyco has many years of experience in cell line glycoengineering and has provided comprehensive and systematic services to scientists worldwide. We are confident to assist your glycobiology research.


Most recombinant biological agents are glycoproteins containing complex oligosaccharides or glycan attachments. Both N-glycosylation and O-glycosylation pathways are the emphases of cellular glycoengineering research. The efficiency and control of glycosylation in the production of recombinant proteins are critical because changes in protein glycosylation will affect the circulating half-life, biological activity and product quality. Improving the degree of glycosylation and sialylation can reduce the clearance rate of treatment products from patients. In addition, controlling the antennarity of glycans helps maintain lot-to-lot consistency during the drug production process. Decreasing core fucosylation can improve antibody effector function and clinical efficacy. Controlling fucosylation can substantially impact the therapeutic effect by regulating antibody-dependent cellular cytotoxicity (ADCC). All in all, glycosylation control is crucial in the development of biotherapeutics.

Therefore, many genetic strategies have been proposed to manipulate glycosylation to change heterogeneity, sialylation, fucosylation and branch structure, such as gene knockdown, knockout, knockin, and overexpression, etc., to further meet the specific needs for the glycosylation mechanism of biopharmaceuticals, thereby promoting the diagnosis and treatment of complex diseases (such as cancer).


We have many production systems to prepare glycoproteins. In mammalian expression systems, Chinese Hamster Ovary (CHO) cells represent the main platform for the production of recombinant biotherapeutic glycoproteins in the biopharmaceutical industry. Taking CHO cells as an example, we provide a complete set of proprietary genetic glycoengineering technologies, including but not limited to:

  • Zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), CRISPER/Cas9 and small interfering RNA (siRNA), short hairpin RNA (shRNA) and other gene-editing technologies, and classic overexpression technologies.
  • We also provide other strategies such as the insertion of glycosylation sites and the manipulation of glycan heterogeneity to generate the desired glycoforms for different biotechnological applications.


  • Design and production of therapeutic glycoproteins
  • Optimization of glycoprotein function
  • Disease diagnosis and treatment
  • Development of the new immunotherapy
  • Glycoprotein structure and function research

Advantages of Us

  • Customize experimental programs according to research needs
  • Systematic technology platforms and optimized production systems
  • PhD-level researchers
  • The reliable and stable manufacturing process
  • One-stop service, 24 hours after-sales service

CD BioGlyco can customize detailed and rigorous experimental procedures according to customers' scientific research needs. Our various advanced technologies can fully meet customer requirements and provide you with first-class and thoughtful genetic glycoengineering services.

Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.


  1. Heffner, K.M.; et al. Glycoengineering of Mammalian Expression Systems on a Cellular Level. Advances in Biochemical Engineering/Biotechnology. 2018.
  2. Spahn, P.N.; Lewis, N.E. Systems glycobiology for glycoengineering. Current Opinion in Biotechnology. 2014, 30: 218-224.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.